Purification, structure features and anti-atherosclerosis activity of a Laminaria japonica polysaccharide
•A homogenous polysaccharide (LJP12) was isolated from Laminaria japonica.•The structural features of LJP12 were characterized.•The anti-atherosclerosis activity of LJP12 was evaluated.•The mechanisms of anti-atherosclerosis of LJP12 were studied. A homogeneous polysaccharide (LJP12) was isolated fr...
Saved in:
Published in | International journal of biological macromolecules Vol. 81; pp. 926 - 935 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
01.11.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | •A homogenous polysaccharide (LJP12) was isolated from Laminaria japonica.•The structural features of LJP12 were characterized.•The anti-atherosclerosis activity of LJP12 was evaluated.•The mechanisms of anti-atherosclerosis of LJP12 were studied.
A homogeneous polysaccharide (LJP12) was isolated from Laminaria japonica by diethylaminoethyl-cellulose and Sephacryl S-500 chromatography, with a molecular weight of 2.31×106Da. Monosaccharide analysis showed that LJP12 was mainly composed of arabinose, xylose, mannose, glucose and galactose in a molar ratio of 1:0.17:1.54:2.64:0.18. For these monosaccharides, mannose was suggested to be 1,4-linked and 1,3,6-linked while glucose was linked by 1,6-glycosidic bond. The xylose, arabinose and galactose were suggested to be the terminal residues. To study the effects of LJP12 on protecting against atherosclerosis, LJP12 was administered to LDL receptor-deficient (LDLr−/−) mice (50, 100 and 200mg/kg/day, n=30 for each experimental group). Results showed that LJP12 exhibited the ability to inhibit high-fat-cholesterol diet (HFD)-induced formation of atherosclerotic plaques and plasma lipid levels in a dose-dependent manner. Meanwhile, both the HFD-induced systemic inflammation and local inflammation at the site of atherosclerotic lesion were significantly attenuated by LJP12, which were accompanied by the suppression of the activation of nuclear factor kappa-B (NF-κB) and mitogen-activated protein kinases (MAPKs) signaling pathways. Taken together, we concluded that long-term oral administration of LJP12 protects against atherosclerosis in LDLr−/− mice via inhibiting NF-κB/MAPKs-mediated inflammatory responses. |
---|---|
ISSN: | 0141-8130 1879-0003 |
DOI: | 10.1016/j.ijbiomac.2015.09.027 |